ClinicalTrials.gg
Sign In
CompletedNCT00332293Updated Nov 18, 2016

AL-15469A for the Treatment of Bacterial Conjunctivitis

A Phase 3 interventional study of Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5% and Moxifloxacin hydrochloride ophthalmic solution 0.5% as base in Bacterial Conjunctivitis, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
695
Allocation
Randomized
Ages
1 Month and older
Sex
All
01

Study summary

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

02

Conditions studied

  • Bacterial Conjunctivitis
03

In context

Conjunctivitis, Bacterial

40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.

This study's enrollment of 695 is above the median of 261 across 36 interventional studies indexed under Conjunctivitis, Bacterial.

Browse Conjunctivitis, Bacterial studies →

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Browse Alcon Research studies →All Alcon studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signs and symptoms of bacterial conjunctivitis
  • Other protocol-defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • under 1 mo. age
  • Other protocol-defined exclusion criteria may apply
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
695 participants (actual)

Study arms

  • Experimental
    Moxifloxacin

    Drug: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%

  • Active comparator
    VIGAMOX

    Drug: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical cure and microbiological success

Secondary outcomes

  1. Individual signs and symptoms of bacterial conjunctivitis at each visit

07

Study locations

1 site
  • Contact Alcon for Trial Locations
    Fort Worth, Texas 76134, United States
08

References and documents

Publications

  • Tauber S, Cupp G, Garber R, Bartell J, Vohra F, Stroman D. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Adv Ther. 2011 Jul;28(7):566-74. doi: 10.1007/s12325-011-0037-x. Epub 2011 Jun 14. PubMed 21681652 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2006
First posted
Jun 1, 2006
Start
May 2006
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00332293
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jun 1, 2006
Start date
May 2006
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Nov 18, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Conjunctivitis, Bacterial →

Other studies from this sponsor

Alcon Research →

Start the discussion